Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents.
D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000209:etiology*; D026661:Clinical Trials Data Monitoring Committees / Q000458:organization & administration*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D018570:Risk Assessment / Q000379:methods*; D014481:United States; D014486:United States Food and Drug Administration
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents